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OBJECTIVE—We investigated the differential roles of apolipo-
protein E (apoE) isoforms in modulating diabetic dyslipidemia—
a potential cause of the increased cardiovascular disease risk of
patients with diabetes.
RESEARCH DESIGN ANDMETHODS—Diabetes was induced
using streptozotocin (STZ) in human apoE3 (E3) or human apoE4
(E4) mice deficient in the LDL receptor (LDLR2/2).
RESULTS—Diabetic E3LDLR2/2 and E4LDLR2/2 mice have in-
distinguishable levels of plasma glucose and insulin. Despite this,
diabetes increased VLDL triglycerides and LDL cholesterol in
E4LDLR2/2 mice twice as much as in E3LDLR2/2 mice. Diabetic
E4LDLR2/2 mice had similar lipoprotein fractional catabolic
rates compared with diabetic E3LDLR2/2 mice but had larger
hepatic fat stores and increased VLDL secretion. Diabetic
E4LDLR2/2 mice demonstrated a decreased reliance on lipid as
an energy source based on indirect calorimetry. Lower phosphor-
ylated acetyl-CoA carboxylase content and higher gene expres-
sion of fatty acid synthase in the liver indicated reduced fatty acid
oxidation and increased fatty acid synthesis. E4LDLR2/2 primary
hepatocytes cultured in high glucose accumulated more intracel-
lular lipid than E3LDLR2/2 hepatocytes concomitant with a 60%
reduction in fatty acid oxidation. Finally, the exaggerated dys-
lipidemia in diabetic E4LDLR2/2 mice was accompanied by a dra-
matic increase in atherosclerosis.
CONCLUSIONS—ApoE4 causes severe dyslipidemia and ath-
erosclerosis independent of its interaction with LDLR in a model
of STZ-induced diabetes. ApoE4-expressing livers have reduced
fatty acid oxidation, which contributes to the accumulation of
tissue and plasma lipids. Diabetes 60:2285–2294, 2011
C
ardiovascular disease (CVD) caused by a wors-
ening of atherosclerosis is an important com-
plication of diabetes and is the leading cause of
mortality among patients with diabetes (1).
Patients with poorly managed type 1 diabetes or type 2 di-
abetes commonly have elevated VLDL triglycerides (TGs),
a reduction of HDL cholesterol, and smaller, dense LDL.
This common cluster of harmful changes in lipid metabo-
lism is referred to as diabetic dyslipidemia (2).
Apolipoprotein E (apoE) is a small circulating protein
associated predominantly with VLDL and HDL. It is the
primary ligand for several lipoprotein receptors, making it
a crucial component in the clearance of lipid from the
circulation and a major determinant of plasma cholesterol
and CVD risk (3). In humans, the APOE gene is polymorphic,
resulting in production of three common isoforms: apoE2,
apoE3, and apoE4. The apoE4 isoform is carried by more
than a quarter (28%) of the U.S. population and is associ-
ated with higher LDL cholesterol and an increased risk of
CVD (3). In addition to its well-established role in CVD,
recent findings have implicated a role for apoE in glucose
metabolism. Epidemiological studies have suggested that
in certain populations, APOE genotype may influence
plasma glucose and insulin levels (4,5), postprandial glu-
cose response (6), the development of metabolic syn-
drome (7,8), and a myriad of diabetes complications (9). In
addition, apoE4 carriers with diabetes have been shown to
have increased carotid atherosclerosis (10), and elderly
apoE4 carriers with diabetes have an increased risk of
CVD-associated death (11).
Increases in VLDL TGs; decreases in HDL; the accu-
mulation of smaller, more dense LDL; slower clearance of
postprandial chylomicrons; and a decrease in LDL re-
ceptor (LDLR) expression are all noted phenotypes asso-
ciated with both type 1 and type 2 diabetes (2). All of these
components of diabetic dyslipidemia are areas of normal
lipid metabolism in which apoE has previously been
shown to play a direct role. The major receptor through
which apoE mediates lipoprotein clearance is the LDLR,
and the apoE isoforms exhibit differential LDLR binding
affinities (12). Therefore, we sought whether apoE iso-
forms retain differential roles in diabetic dyslipidemia and
atherosclerosis in the absence of the LDLR by using a
mouse model of diabetes induced by streptozotocin (STZ).
In this study, we show that dyslipidemia and atheroscle-
rosis are greatly exaggerated in diabetic LDLR2/2 mice
expressing human apoE4 (E4LDLR2/2) compared with
those with human apoE3 (E3LDLR2/2), despite a similar
degree of hyperglycemia. This E4-specific aggravation of
diabetic dyslipidemia is central to the liver and is associated
with a reduction in hepatic lipid oxidation, an accumulation
of liver TGs, and increased rates of VLDL secretion.
RESEARCH DESIGN AND METHODS
Mice and induction of diabetes. Mice homozygous for replacement of the
endogenous Apoe gene with the human APOE*3 (E3) or APOE*4 (E4) allele
(13,14) were crossed with mice deficient in the LDLR (15). All mice were on
C57BL/6 backgrounds. Male mice were fed normal chow diet ad libitum (5.3%
fat and 0.02% cholesterol; Prolab IsoPro RMH 3000, Agway Inc., Syracuse, NY).
Diabetes was induced at 2 months of age by peritoneal injections of STZ for 5
consecutive days (0.05 mg/g body wt in 0.05 mol/L citrate buffer, pH 4.5). Mice
maintaining glucose levels .300 mg/dL throughout the course of the study are
considered “diabetic.” “Nondiabetic” control mice were injected with vehicle
citrate buffer. Biochemical analyses were carried out at 1 month post-STZ un-
less otherwise stated. Animals were handled under protocols approved by the
institutional animal care and use committees of the University of North Carolina.
Biochemical assays. After a 4-h fast, animals were anesthetized with 2,2,2-
tribromoethanol and blood was collected. Plasma glucose, cholesterol, phos-
pholipids, free fatty acids (FFAs), and ketone bodies were measured using
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commercial kits (Wako, Richmond, VA). TGs and insulin were determined
using commercial kits from Stanbio (Boerne, TX) and Crystal Chem Inc.
(Downers Grove, IL), respectively. Liver TGs were extracted as described (16).
Lipoprotein distribution and composition was determined with pooled (n = 6–8)
plasma samples (100 mL) fractionated by fast-protein liquid chromatography
using a Superose 6 HR10/30 column (GE Healthcare, Piscataway, NJ). Pooled
plasma (800 mL) was separated by sequential density ultracentrifugation into
density fractions from ,1.006 g/mL (VLDL) to .1.21 g/mL (HDL) and subjected
to electrophoresis in a 4–20% denaturing SDS-polyacrylamide gel (17). Carbox-
ylmethyl lysine (CML) advanced glycation end products (AGEs) were measured
using an enzyme-linked immunosorbent assay (ELISA) with antibodies specific
for CML-AGEs (CycLex, Nagano, Japan). ApoE and apoCIII were measured
using an ELISA with antibodies specific for apoE (Calbiochem, San Diego, CA)
and apoCIII (Abcam, Cambridge, MA). Protein expression by Western blot was
determined using antibodies against AMP-activated protein kinase (AMPK)-a,
phosphorylated (Thr172) AMPK (pAMPK)-a, acetyl-CoA carboxylase (ACC),
phosphorylated (Ser79) ACC (pACC), and b-actin (Cell Signaling, Boston, MA).
Lipid tolerance test was performed by gavaging 10 mL/kg olive oil after an
overnight fast. For VLDL secretion, plasma TG was measured after injection of
Tyloxapol (Triton WR-1339, Sigma, St. Louis, MO) via tail vein (0.7 mg/g body wt)
after a 4-h fast (18). VLDL lipolysis was estimated by incubating VLDL (25 mg TG
in 60 mL PBS) at 37°C with 15 units of bovine lipoprotein lipase (Sigma). The
reaction was stopped by adding 3 mL of 5 mol/L NaCl, and fatty acid release
(FAtimepoint 2 FA0) was measured as above.
Lipoprotein clearance. VLDL and LDL were labeled with 1,19-Dioctadecyl-
3,3,39,39-tetramethylindocarbocyanine iodide (DiI) or 125I as previously described
and injected to recipient mice via the tail vein (100 mg DiI-VLDL or 5 3 105
counts 125I lipoproteins, diluted in 200 mL PBS) (18). Plasma fluorescence was
measured using an Olympus FV500 (Texas Red filter) with a SPOT 2 digital
camera. Radioactivity was counted on a Wallac 1470 Wizard g Counter (EG&G
Wallac, Gaithersburg, MD).
Lipid and glucose uptake, de novo lipogenesis, and oxidation. Primary
hepatocytes were isolated from 3-month-old mice as described (19). Yield
ranged from 3 to 6 3 106 cells/g liver and viability (assessed by Trypan blue
staining) was .90%. After overnight culture in hepatocyte media (Xenotech,
Lenexa, KS), cells (100,000/well, 24-well plate) were washed and cultured 72 h
in Dulbecco’s modified Eagle’s medium supplemented with 5% FBS (volume
for volume) with 5 mmol/L (low) or 25 mmol/L (high) glucose. Prior to di-
lution, [1-14C]palmitic acid was resuspended in 1% BSA solution. For oxidation
measurements, cells were incubated for 2 h with 1 mCi/mL D-[1-14C]glucose or
1 mCi/mL [1-14C]palmitic acid (PerkinElmer, Waltham, MA) while CO2 was
trapped using a customized 48-well NaOH trap (20). For 2-Deoxyglucose up-
take, hepatocytes were starved in serum-free medium containing 135 mmol/L
NaCl, 5.4 mmol/L KCl, 1.4 mmol/L CaCl2, 1.4 mmol/L MgSO4, and 10 mmol/L
Na4P2O7 for 30 min and then incubated for 10 min with 1 mCi/mL 2-Deoxy-D
[1-3H]glucose (PerkinElmer). For fatty acid uptake and 2-Deoxyglucose up-
take, cells were washed three times with ice-cold Hanks’ balanced salt solu-
tion, lysed in 1 mL of 1% SDS, and radiation counted. To estimate de novo
lipogenesis (DNL), cells were incubated with 1 mCi/mL D-[1-14C]glucose for
24 h, washed three times with PBS, scraped in 1 mL of methanol-to-PBS (2:3),
and freeze thawed in liquid nitrogen. The lipid layer was then extracted using
a chloroform-to-methanol (2:1) extraction. Radiation was counted in 5 mL
SX18–4 Scinteverse BD scintillation fluid (Fisher, Pittsburgh, PA) using an LKB
Wallac 1214 RackBeta liquid scintillation counter (Spectrofuge, Durham, NC).
Indirect calorimetry. Mice were placed in a calorimetry system (LabMaster,
TSE Systems, Chesterfield, MO) for 48 h and monitored for O2 consumption, CO2
production, and RQ (RQ = VCO2/VO2, where V is volume). Activity was determined
by counting the number of breaks in light barriers on the X-, Y-, and Z-axis.
Atherosclerosis. After 3 months of diabetes, mice were killed with a lethal
dose of 2,2,2-tribromoethanol and perfused at physiological pressure with 4%
phosphate-buffered paraformaldehyde (pH 7.4). Morphometric analysis of
plaque size at the aortic root was performed as described (19). Apoptotic cells
were detected in 8-mm frozen sections of the aortic root with a kit that detects
DNA fragmentation (Chemicon, Billerica, MA). Macrophages were detected
with a 1:500 dilution of MOMA-2 (Abcam) and a 1:2,000 dilution of goat
polyclonal secondary antibody to rat IgG - H&L Cy5 (Abcam).
RESULTS
Induction of diabetes. E3LDLR2/2 and E4LDLR2/2 mice
had indistinguishable plasma glucose levels at the begin-
ning and at the end of the study (Fig. 1A and Table 1). They
showed a similar response rate to STZ, with 86.4 and 84.6%
of injected E3LDLR2/2 and E4LDLR2/2 mice becoming
diabetic. One month after STZ injection, average plasma
glucose levels of E3LDLR2/2 and E4LDLR2/2 mice reached
424 6 30 and 407 6 44 mg/dL, respectively, and remained
.400 mg/dL for the 3-month study period (Fig. 1A and
Table 1). Plasma insulin levels in both genotypes dropped
severely (Fig. 1B). The severity of diabetes was also
comparable between the two diabetic groups as estimated
by plasma levels of ketone bodies, daily food intake, and
urine excretion (Table 1).
Diabetic dyslipidemia. Nondiabetic E3LDLR2/2 and
E4LDLR2/2 mice had similar total plasma cholesterol and
TGs (Fig. 2A and B) as well as similar lipoprotein distri-
bution profiles (Fig. 2C and D). While the induction of di-
abetes led to increases in total cholesterol and total TGs in
both E3LDLR2/2 and E4LDLR2/2 mice as early as 1 month
after STZ administration, the increase in plasma choles-
terol was significant only in E4LDLR2/2 mice when com-
pared with their nondiabetic counterparts. Most important,
plasma cholesterol and TGs in the diabetic E4LDLR2/2 mice
were significantly higher than those in diabetic E3LDLR2/2
mice at 1 and 3 months of diabetes (Fig. 2A and B).
VLDL and LDL cholesterol, as well as VLDL TGs, in-
creased in both genotypes after STZ administration (Fig.
2E and F). However, VLDL TGs and LDL cholesterol were
both twofold higher in E4LDLR2/2 mice than in E3LDLR2/2
mice (Fig. 2E and F). Consequently, the LDL-to-HDL ratio, an
established risk factor for atherosclerosis, was 2.2-fold higher
in diabetic E4LDLR2/2 mice than in diabetic E3LDLR2/2










mice (n = 8–12 per
group). B: Fasting plasma insulin, as determined by ELISA. **P < 0.01.
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mice. Given that the diet provided was low in fat and cho-
lesterol, food consumption did not differ between the two
diabetic groups (Table 1); the enhanced hyperlipidemia in
E4LDLR2/2 is independent of dietary lipid intake.
VLDL fractionated from plasma by sequential ultracen-
trifugation had a similar composition of cholesterol, TGs,
and phospholipids (Supplementary Fig. 1A). Diabetes in-
duced a 5 and 26% increase in apoB100 and a 10 and 57%
increase in apoB48 in E3LDLR2/2 and E4LDLR2/2 mice,
respectively. Although total amounts of apoB100 and
apoB48 are ;30% more in the diabetic E4LDLR2/2 mice
compared with diabetic E3LDLR2/2 mice, their distribu-
tions among different classes of lipoproteins were not sig-
nificantly altered (Supplementary Fig. 1B–E). In a similar
manner, the amount of total plasma apoA1 did not differ by
apoE genotype (Supplementary Fig. 1F and G). Diabetic
E3LDLR2/2 and diabetic E4LDLR2/2 mice had similar lipo-
protein distributions of apoE (Supplementary Fig. 2A and B)
and apoCIII-to-apoE ratios, an important marker of lipolysis
and uptake (Supplementary Fig. 2C). Rates of lipolysis
were also similar between VLDL isolated from diabetic
E3LDLR2/2 or diabetic E4LDLR2/2 mice (Supplementary
Fig. 2D), suggesting similar rates of VLDL conversion be-
tween the two diabetic groups. In addition, the degree of
glycation in the VLDL-LDL fractions was similar in all
groups (Table 1).
In summary, diabetic E4LDLR2/2 mice develop a far
more deleterious plasma lipid and lipoprotein distribution
profile than diabetic E3LDLR2/2 mice, characterized by
a substantial increase in the total amount of circulating
lipoproteins, although not in the composition of the lipo-
protein particles themselves.
Lipoprotein clearance and postprandial fat tolerance.
As the model used lacks the LDLR, we measured the ex-
pression of several other genes involved in lipoprotein up-
take. The expression of apoE, LDLR related protein 1 (LRP1),
scavenger receptor B type 1 (SR-B1), and N-deacetylase/
N-sulfotransferase 1 (NDST1) did not differ significantly
between the two diabetic groups nor by induction of diabetes
(Fig. 3A). Gene expression of VLDL receptor (VLDLR) was
increased approximately eightfold by STZ administration, but
the difference between diabetic E3LDLR2/2 and E4LDLR2/2
mice was not significant.
We next measured the efficiency of VLDL clearance in
diabetic E3LDLR2/2 and diabetic E4LDLR2/2 mice by in-
jecting VLDL isolated from apoE-deficient mice and labeled
with DiI. There was no difference in the fractional catabo-
lism of VLDL between the two diabetic groups (Fig. 3B). In
a similar manner, there was no difference in the clearance
of LDL particles isolated from nondiabetic LDLR2/2 mice
(Fig. 3C). We also examined whether the lipoprotein par-
ticles from diabetic mice with apoE3 or apoE4 are cleared
differently by injecting nondiabetic LDLR2/2 recipients of
125I-labeled VLDL or LDL isolated from diabetic E3LDLR2/2
or diabetic E4LDLR2/2 mice. There was no difference in
their clearance (Supplementary Fig. 3A and B). These data
demonstrate that the clearance of VLDL remnants and LDL
are not the major cause of the enhanced diabetic dyslip-
idemia observed in E4LDLR2/2 mice compared with
E3LDLR2/2 mice.
Plasma TG levels in the diabetic E4LDLR2/2mice dropped
to similar levels in E3LDLR2/2 mice after an overnight fast.
After administration of an oral gavage of olive oil to the di-
abetic mice, however, plasma TG levels of the E4LDLR2/2
mice quickly reestablished a level twofold higher than
E3LDLR2/2 mice and remained high at all points post-
gavage (Fig. 3D). Except for the initial increase, clear-
ance appeared to be equally impaired in the two groups,
suggesting that diabetes is affecting postprandial lipid
clearance equally. Intestinal absorption assessed by olive
oil gavage after Tyloxapol injection did not differ by apoE
genotype (Supplementary Fig. 4).
VLDL secretion. Altered hepatic VLDL secretion is a pos-
sible contributing factor to the elevated plasma lipids in the
diabetic E4LDLR2/2 mice. Thus, we measured plasma ac-
cumulation of TGs as a marker of VLDL secretion. After
inhibition of VLDL uptake and lipolysis by injection of the
detergent Tyloxapol, the TG secretion rate in nondiabetic
E3LDLR2/2 and E4LDLR2/2 mice was similar, averaging
3.2 6 0.5 and 4.0 6 0.4 mg/dL/min TGs, respectively (Fig.
3E). The secretion rate in the diabetic E3LDLR2/2 mice did
not differ significantly from those of nondiabetic animals,
averaging 3.5 6 0.6 mg/dL/min TGs. In contrast, the secre-
tion rate in the diabetic E4LDLR2/2 mice was significantly
elevated, averaging 7.0 6 0.5 mg/dL/min and reaching
a mean plasma TG level of 1,431.3 6 49.3 mg/dL 2 h after
Tyloxapol injection (Fig. 3E).
Energy usage, hepatic lipid stores, and fatty acid
metabolism. To assess global energy metabolism in the
diabetic E3LDLR2/2 and E4LDLR2/2 mice, indirect calo-
rimetry analysis was performed. Diabetic E4LDLR2/2 mice
had significantly higher daily respiratory exchange ratios
(RERs; VCO2/VO2), particularly during the light cycle, than
E3LDLR2/2 mice (Fig. 4A and B). This difference in RER
was not because of altered activity (data not shown). A
higher average RER in the diabetic LDLR2/2 mice with E4
TABLE 1
Metabolic parameters of LDLR2/2 mice expressing human apoE3 or apoE4
E3LDLR2/2 E4LDLR2/2 Diabetic E3LDLR2/2 Diabetic E4LDLR2/2
Body weight (g) 29.5 6 0.9 30.2 6 1.3 23.9 6 0.9† 24.6 6 1.0†
Total cholesterol (mg/dL) 338.5 6 14.4 372.4 6 42.7 449.7 6 46.7 795.9 6 56.4*†
Total TGs (mg/dL) 296.9 6 24.7 311.2 6 26.5 431.8 6 56.3 624.8 6 48.1*†
FFAs (mmol/L) 0.92 6 0.09 0.91 6 0.10 1.16 6 0.08 1.47 6 0.05*†
Glucose (mg/dL) 146.3 6 6.1 151.3 6 4.9 470.8 6 16.3† 479.3 6 21.4†
Insulin (ng/mL) 0.42 6 0.07 0.48 6 0.12 0.01 6 0.01† 0.03 6 0.01†
Ketone bodies (mmol/L) 87.8 6 27.4 122.5 6 16.7 231.0 6 43.9† 244.5 6 49.7†
Lipoprotein AGEs (mg/mL) 2.02 1.95 2.30 2.38
Food consumed (g/day)# 4.8 6 0.7 5.7 6 1.1 11.9 6 1.3† 12.6 6 1.9†
Urine excretion (mL/day)# 2.0 6 0.2 1.7 6 0.2 13.8 6 0.5† 13.6 6 0.3†
Data are means 6 SD. For the diabetic groups, measurements were taken 3 months after STZ administration (n = 8–18 per group). *P . 0.05,
genotype effect. †P . 0.05, treatment effect. #n = 4–5 per group.
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(0.915 6 0.003) compared with those with E3 (0.896 6
0.004, P , 0.01) during the light cycle indicates that the
presence of apoE4 results in a lower fractional reliance on
lipid as an energy source.
Nondiabetic E3LDLR2/2 and E4LDLR2/2 mice had
similar TG stores in the liver. It is interesting that diabetes
induced a significant accumulation of hepatic TGs only in
E4LDLR2/2 mice, because they store twice as much as
diabetic E3LDLR2/2 mice (Fig. 4C). This increase was not
sufficient to cause overt steatosis, and there were no no-
table histological abnormalities in the livers of the diabetic
mice (data not shown). The increase in hepatic TG storage
in E4LDLR2/2 mice during diabetes was also associated
with an increase in plasma FFAs (Table 1).
Diabetes increased hepatic gene expression of SREBP1c
and FOXO1, regulators of lipogenesis and VLDL secretion,
respectively. Both tended to be higher in diabetic E4LDLR2/2
mice compared with diabetic E3LDLR2/2 mice, but the
FIG. 2. Plasma lipids and lipoprotein profiles. A and B: Total plasma cholesterol (A) and TGs (B) after a 4-h fast (n = 8–18). C and D: Pooled (n =
6–8) plasma samples were separated into lipoprotein fractions by fast protein liquid chromatography. Lipoprotein cholesterol (C) and TG (D)









mice. *P < 0.05 and **P < 0.01.
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FIG. 3. Lipoprotein clearance and secretion. A: Liver mRNA levels of apoE, LRP, VLDLR, SR-B1, and NDST1. Data are expressed relative to
nondiabetic mice (n = 6–7). B and C: Lipoprotein clearance. VLDL (B) and LDL (C) were isolated from plasma of APOE2/2 mice and LDLR2/2 mice,




mice after a 4-h fast. D: Postprandial lipid tol-




mice following an oral gavage of olive oil after overnight fast
(n = 6–8). E: VLDL secretion. Plasma TGs of nondiabetic E3LDLR2/2, nondiabetic E4LDLR2/2, diabetic E3LDLR2/2, and diabetic E4LDLR2/2
mice after injection of Tyloxapol (n = 4–6 per group). *P < 0.05 and **P < 0.01.
L.A. JOHNSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, SEPTEMBER 2011 2289
increase did not reach significance (Fig. 4D). Expression
of genes for SREBP2, ChREBP, PPAR-a, and CPT1 did not
alter significantly between the two genotypes. It is important
that expression of fatty acid synthase decreased signifi-
cantly in E3LDLR2/2 livers after STZ administration while
remaining elevated in diabetic E4LDLR2/2 livers (Fig. 4D).
Although protein levels of AMPK and pAMPK were similar,
a significantly lower pACC-to-ACC ratio was noted in livers
isolated from diabetic E4LDLR2/2 mice compared with
E3LDLR2/2 livers (Fig. 4E and F). Total ACC also tended
to be lower but did not reach significance. A lower pACC-
to-ACC ratio is indicative of decreased fatty acid oxidation
and increased fatty acid synthesis. Together, these data
suggest that increased fatty acid synthesis and reduced




mice using indirect calorimetry (n = 4). C: Hepatic TG content. Liver TG was measured after homogenization and





mice. Data are expressed relative to nondiabetic mice (n = 8–14). E: Livers from diabetic E3LDLR2/2 and
diabetic E4LDLR
2/2
mice were homogenized and protein expression of pAMPK, total AMPK, pACC, and total ACC was determined by Western
blot analysis (n = 4). F: Band intensity from E was quantitated using ImageJ software. Data are expressed relative to diabetic E3LDLR2/2 in
arbitrary units (AUs). *P < 0.05 and **P < 0.01.
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fatty acid oxidation underlie an accumulation of lipid
stores in the livers of diabetic E4LDLR2/2 mice.
Glucose and lipid metabolism in primary hepatocytes.
To verify a decrease in fatty acid oxidation in the livers
of diabetic E4LDLR2/2 mice, primary hepatocytes were
isolated and cultured for 72 h in high (25 mmol/L) glucose
medium to mimic the hyperglycemic environment of
diabetes. Control cells were incubated in low glucose
(5 mmol/L) for the same period. Similar to the TG accu-
mulation noted in the liver in vivo, primary hepatocytes
harvested from E4LDLR2/2 mice and cultured in high
glucose accumulated more lipid than E3LDLR2/2 cells
(Fig. 5A and B). The total area of lipid per cell was two-
fold higher in cells expressing E4 than E3 (16.6 6 1.9 and
7.7 6 0.6 mm2/cell, respectively) (Fig. 5B).
FFA uptake, measured using [14C]palmitic acid, increased
in hepatocytes cultured in the high glucose medium but was
not affected by apoE isoform (Fig. 5C). In a similar manner,
there was no apoE isoform effect on the cellular uptake of
glucose (Fig. 5D). The rate of DNL, defined here as 14C in-
corporation into the lipid layer in cells cultured in the
presence of [14C]glucose, was higher in hepatocytes cul-
tured in high glucose medium than those cultured in low
glucose medium. However, hepatocytes isolated from
E3LDLR2/2and E4LDLR2/2mice did not differ in their rate of
DNL in either the low or high glucose environment (Fig. 5E).
We next examined the rates of glucose and lipid oxi-
dation in the E3LDLR2/2 and E4LDLR2/2 hepatocytes.
Three days in high glucose medium decreased rates of
[14C]glucose oxidation in both E3LDLR2/2 and E4LDLR2/2
hepatocytes. However, there was no significant difference
in glucose utilization between them (Fig. 5F). Finally, we
measured lipid oxidation in primary hepatocytes cultured in
high or low glucose using [14C]palmitic acid. E3LDLR2/2
and E4LDLR2/2 hepatocytes cultured in the low glucose
media demonstrated similar rates of lipid oxidation. When
cultured in the high glucose environment, however, there
was a striking downregulation of lipid oxidation only
in E4LDLR2/2 hepatocytes (Fig. 5G). After 72 h in the
high glucose condition, the E4LDLR2/2 hepatocytes had
lipid oxidation rates ;40% of those in the E3LDLR2/2
hepatocytes.
Diabetic atherosclerosis. Reflecting their severe dys-
lipidemia, diabetic LDLR2/2 mice carrying the E4 allele
had aortic plaques on average threefold greater in area
than those with E3 (Fig. 6). The size of the atherosclerotic
plaques in diabetic E4LDLR2/2 mice (141,0006 19,000 mm2)
was significantly greater when compared with diabetic
E3LDLR2/2 mice (48,000 6 9,000 mm2) as well as to
both nondiabetic E3LDLR2/2 and nondiabetic E4LDLR2/2
mice (32,000 6 8,000 and 40,000 6 12,000 mm2) (Fig. 6).
While diabetic E4LDLR2/2 mice had larger and more
complex atherosclerotic lesions than diabetic E3LDLR2/2
mice, the number of macrophages (Supplementary Fig. 5A
and B) and apoptotic cells (Supplementary Fig. 5C and D)
per lesion area were similar between the two groups.
DISCUSSION
In the present work, we explored the isoform-specific
role of apoE in diabetic dyslipidemia using diabetic
LDLR2/2 mice with human apoE4 or apoE3. We found that
1) nondiabetic E3LDLR2/2 and E4LDLR2/2 mice are in-
distinguishable in all parameters of glucose and lipid me-
tabolism measured in this study; 2) after induction of
diabetes, E4LDLR2/2 mice, but not E3LDLR2/2, develop
enhanced dyslipidemia, characterized by elevated VLDL
TG and LDL cholesterol, and an increased rate of VLDL
secretion; 3) the severe dyslipidemia in diabetic E4LDLR2/2
mice is associated with larger hepatic lipid stores and a
calorimetric profile suggestive of lower lipid utilization;
4) primary hepatocytes isolated from E4LDLR2/2 mice and
cultured in high glucose accumulated more intracellular lipid
concomitant with a reduction in fatty acid oxidation; and
5) these metabolic disturbances during diabetes culminated
in exaggerated atherosclerosis only in E4LDLR2/2 mice.
Diabetic dyslipidemia in poorly treated type 1 diabetes
and type 2 diabetes shares many features (2). In many
patients with diabetes, the levels of circulating lipoproteins
during fasting are relatively normal (21). Instead, the major
impairments to lipoprotein metabolism occur with their
ability to clear postprandial lipoproteins (2). The prolonged
elevation of plasma TGs after a fatty meal has been dem-
onstrated in individuals carrying the E4 allele (6), and our
previous work demonstrated postprandial lipemia in LDLR
overexpressing mice with human apoE4 (22). Previously,
Goldberg et al. (23) showed that STZ-induced diabetic
LDLR2/2 mice accumulated a “subclass of lipoproteins”
that normally is quickly removed from the circulation. Our
experiments confirmed that postprandial lipid clearance
is impaired in diabetic LDLR2/2 mice. However, except
for initial increase in plasma TG in E4LDLR2/2 mice, the
postprandial clearance rate was not different in two groups.
In addition, we found no APOE genotype effect on the
fractional catabolism of either VLDL or LDL.
VLDL production is increased in type 2 diabetes and in
uncontrolled type 1 diabetes (2). In insulin-resistant patients,
this increased VLDL production is oftentimes part of a dys-
lipidemic cycle in which larger adipose tissue stores are
associated with increased FFA release (24). In turn, an in-
creased flux of FFA to the liver stimulates VLDL secretion
(25). The FFA-stimulated VLDL production is compounded
in an insulin-resistant or insulin-deficient state (2). Along
these lines, the increased plasma VLDL in the diabetic
E4LDLR2/2 mice is accompanied by a twofold increase in
TG secretion. In comparison, TG secretion in the diabetic
E3LDLR2/2 mice was not different from that in the non-
diabetic controls. In a similar manner, LDLR2/2 mice
expressing murine apoE do not have increased rates of
TG production after STZ-induced diabetes (23). We note
that increased hepatic secretion of TG-rich particles is
most likely responsible for the majority of LDL-sized
particles in E4LDLR2/2 mice, since absence of LDLR has
been shown to result in overproduction of TG-rich par-
ticles smaller than normal VLDL (26,27). Thus, the dys-
lipidemic cycle commonly seen in patients with insulin
resistance is reflected by the insulin-deficient E4LDLR2/2
mice used in this study, which have higher circulating FFA,
larger hepatic TG stores, and higher rates of TG secretion
than diabetic E3LDLR2/2 mice.
Indirect calorimetry analysis revealed a clear apoE ge-
notype effect on energy usage during diabetes at the whole
body level. Diabetic E4LDLR2/2 mice had significantly
higher RER, demonstrating a lower ratio of lipid-to-
carbohydrate oxidation compared with diabetic E3LDLR2/2
mice during the light cycle. This reduced reliance on lipid
oxidation appears to be central to the liver and directed by
ACC signaling. When active, ACC catalyzes the production
of malonyl-CoA, thereby stimulating lipogenesis and inhib-
iting the b-oxidation of fatty acids (28). A significant re-
duction in the pACC-to-ACC ratio in the livers of diabetic
E4LDLR2/2 mice indicates an increase in lipogenesis and
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decrease in fatty acid oxidation. In addition, STZ adminis-
tration decreased FASN gene expression in the E3LDLR2/2
mice, as previously reported in wild-type mice (29). How-
ever, this diabetes-induced reduction did not occur in
E4LDLR2/2 mice, suggesting a higher rate of fatty acid
synthesis in these mice. Higher expression of FASN
was not the result of stimulation by ChREBP. Expression
of SREBP1c, an important regulator of FASN-directed
lipogenesis, on the other hand, tended to be higher in the
diabetic E4LDLR2/2 livers but did not reach significance.
Regardless, these data point toward two distinct means
(metabolically linked by ACC signaling) by which lipid
accumulates in the E4LDLR2/2 livers during diabetes—
an increase in fatty acid synthesis and a reduction in fatty
acid oxidation. Consistent with these data, apoE4-expressing
LDLR2/2 hepatocytes cultured in high glucose reduced their
rate of lipid oxidation to levels ;40% of that in E3LDLR2/2
hepatocytes and amassed more than twice as much lipid.
FIG. 5. Metabolic analyses of primary hepatocytes. A: Primary hepatocytes from E3LDLR2/2 or E4LDLR2/2 mice were cultured for 72 h in high
glucose (25 mmol/L) media and stained with Oil Red O to highlight lipid droplets. B: Total lipid droplet area per cell was quantified by measuring 50
randomly chosen cells from four separate cultures per group. C: Fatty acid uptake was estimated by counting intracellular radiation after in-
cubating hepatocytes for 1 min with 2 mCi/mL [14C]palmitate. D: Glucose uptake was measured after a 10-min incubation with 1 mCi/mL 3H-2-
deoxyglucose after starving cells for 2 h. E: DNL was measured by counting radiation in the lipid layer after 24-h incubation with [14C]glucose.
F and G: Oxidation of [14C]glucose (F) and [14C]palmitate (G) was measured by trapping 14CO2 during a 3-h incubation using a customized, self-
contained CO2 trap (n = 4–12 wells per trial, three trials per group). *P < 0.05 and **P< 0.01. (A high-quality color representation of this figure is
available in the online issue.)
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LDLR2/2 mice are an established model for high-fat
diet–induced obesity and insulin resistance, and we have
previously shown that mice expressing apoE4 are more
susceptible to diet-induced glucose intolerance than
those expressing apoE3 (30). This propensity of apoE4-
expressing mice to develop glucose intolerance likely
contributes to the impaired lipid metabolism in the insulin-
deficient state. In this context, we note that VLDLR mRNA
was significantly increased after the STZ administration,
and the mRNA levels tended to be higher in the diabetic
E4LDLR2/2 livers than in the diabetic E3LDLR2/2 livers.
While the contribution of VLDLR in hepatic remnant
clearance during diabetes is not clear, fasting hyper-
triglyceridemia in VLDLR2/2 mice has been previously
noted (31), and when overexpressed in the liver, VLDLR
appears to function similarly to LDLR and LRP (32). The
VLDLR plays an important role in adipocyte TG accumula-
tion (33) and could be a potential player in the process of
hepatic lipid accumulation during diabetes.
Our results support the possibility that apoE functions
as a metabolic signaling molecule outside its established
role in lipoprotein clearance. For example, a role for apoE
as a signaling molecule has been shown previously in the
context of Alzheimer disease (34), where it has been
shown to affect activation of extracellular signal-regulated
kinase 1/2 and c-Jun NH2-terminal kinase in an apoE
isoform–specific manner (35). Similar apoE4-specific sig-
naling could account for some of the metabolic abnor-
malities during diabetes highlighted in this study.
Alternatively, apoE has been shown to enhance VLDL
secretion (36), as well as play a role in the accumulation
of lipid in early and intermediary secretory compartments
of hepatocytes (37). Thus, inefficient recycling and rese-
cretion of apoE4 (38) could potentially affect the avail-
ability, packaging, and/or transport of TG from the
hepatic lipid pool. Irrespective of the precise mode of
action, our results demonstrate a possible chain of events
in diabetic E4LDLR2/2 livers; a downregulation of lipid
oxidation and upregulation of fatty acid synthesis lead to
larger hepatic TG stores, which in turn drive an increase
in VLDL secretion. Combined with marked diabetic
effects that impair VLDL and postprandial TG clearance,
these processes are ultimately responsible for the severe
dyslipidemia observed in the diabetic E4LDLR2/2 mice.
It is important that the diabetes-induced acceleration of
atherosclerosis occurs only in LDLR2/2 mice expressing
apoE4. Previous studies of STZ-induced diabetes in
LDLR2/2 mice have produced variable results, with some
groups showing an increase in atherosclerosis (39,40)
while others show no change (41,42). Although the rea-
sons for these mixed results are unknown, varying ex-
perimental conditions, such as diet, could contribute (43).
The E4-specific acceleration of atherosclerosis is likely
a direct result of the severe dyslipidemia brought about
by STZ-induced diabetes in these mice, although con-
tributions of other factors, such as apoE4-specific effects
on macrophages, cannot be excluded (44). Regardless,
our data clearly demonstrate the presence of E4 effects
that are independent of the LDLR. Moreover, the exag-
gerated dyslipidemia and atherosclerosis observed in the
diabetic E4LDLR2/2 mice extends beyond the scope of
type 1 diabetes and has implications for the growing
number of apoE4 carriers with insulin resistance and type
2 diabetes. In conclusion, the apoE4-specific atheroscle-
rosis and diabetic dyslipidemia illustrated in this study
may also play an important role in patients with diabetes
who carry the apoE4 isoform.
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